Toxic Traits of This Flower May Hold Clues for Safer Drug Development

Researchers at Northeastern University have discovered a mammal-like hormonal pathway in plants such as foxglove that could lead to safer and more efficient production of heart and cancer drugs. The findings, published in Science Advances, reveal how toxic molecules like those in digoxin are formed in plants, offering a potential pathway to develop medications with improved safety profiles.

Digoxin, a medication derived from foxglove leaves, has long been used to regulate heart muscle function but requires approximately 1,000 kilograms of dried leaves to produce just one kilogram of the drug. This inefficient extraction process, combined with digoxin’s narrow therapeutic window — where doses outside a precise range can become highly toxic — has limited its broader use and raised safety concerns.

The research team, led by post-doctoral researcher Menglong Xu and professor Jing-Ke Weng from Northeastern’s Department of Chemistry and Chemical Engineering, identified that foxglove and other organisms like fireflies and toads have independently evolved similar toxic defense mechanisms. This phenomenon, termed “cross-kingdom endocrine mimicry,” occurs when organisms from different biological kingdoms develop hormonal characteristics that allow them to interact with each other’s systems.

By uncovering how plants biosynthesize these potent compounds, the scientists aim to engineer safer versions of cardiac glycosides — the class of chemicals to which digoxin belongs — that retain therapeutic benefits while reducing toxicity risks. The same biosynthetic insights could also be applied to modify these molecules for use in cancer treatments, expanding their potential beyond heart disease.

Currently, the cultivation and purification of foxglove for digoxin production places significant agricultural and manufacturing burdens on supply chains. A biosynthetic approach, potentially using microbial fermentation or plant cell cultures, could overcome these inefficiencies and provide a more scalable and controllable method for producing these critical drugs.

Although the research is still in its early stages, the identification of shared hormonal pathways across kingdoms opens new avenues for drug design. By mimicking nature’s own mechanisms for producing and regulating toxic compounds, scientists may develop next-generation therapeutics that are both more effective and safer for patients.